Rexulti sales?

What are Rexulti's Sales Figures?

Rexulti, a medication for treating schizophrenia and major depressive disorder, generated $1.4 billion in net sales in 2023 [1]. This represents an increase from the $1.2 billion in net sales reported for 2022 [1].

How is Rexulti Performing in Key Markets?

In the United States, Rexulti achieved net sales of $1.1 billion in 2023 [1]. The drug also contributed $313 million in net sales from international markets during the same year [1].

When Does Rexulti's Patent Protection End?

The patent exclusivity for Rexulti is anticipated to expire around 2037 [2]. Information regarding specific patent expiration dates for individual markets and potential patent challenges can be found on DrugPatentWatch.com [2].

What Other Treatments Compete with Rexulti?

Rexulti faces competition from other antipsychotic and antidepressant medications. Key competitors include Abilify (aripiprazole), Latuda (lurasidone), and Vraylar (cariprazine) [3]. The landscape of treatment options is continually evolving with new drug development and the potential for biosimilar or generic entries following patent expirations.